Relapsed / Refractory Mantle Cell Lymphoma (MCL) Clinical Trial
Official title:
A Single-arm, Multicenter Phase II Clinical Trial of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)
This is a study to evaluate the safety and efficacy of TQ-B3525 tablets in patients with relapsed / refractory mantle cell lymphoma (MCL).
| Status | Recruiting |
| Enrollment | 102 |
| Est. completion date | September 2021 |
| Est. primary completion date | September 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - 1. Understood and signed an informed consent form; 2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2; Life expectancy = 3 months; 3. Relapsed / refractory MCL; 4. Has received at least one-line and less than four lines of previous treatment, the latest treatment confirmed no objective response, or disease progress after treatment; 5. Has at least one measurable lesion; 6. Adequate organ system function; 7. Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ;No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the first administration. Exclusion Criteria: - 1. Has central nervous system violation; 2. Has received other PI3K inhibitors; 3. Has diagnosed and/or treated additional malignancy within 3 years prior to the first administration; 4. Has history of interstitial lung disease; 5. Has a history of immunodeficiency diseases; 6. Has multiple factors affecting oral medication; 7. Has adverse events caused by previous therapy except alopecia that did not recover to =grade 1; 8. Has received systemic steroid treatment within 7 days before the first administration; 9. Has received other systemic anti-tumor medications within 4 weeks before the first administration, or still within the 5 half-life of the medication, which occurs first; 10. Has palliative radiation therapy within 4 weeks before the first administration; 11. Has active infections within 4 weeks before the first administration; 12. Has received surgery, or unhealed wounds within 4 weeks before the first administration; 13. Has a history of autologous hematopoietic stem cell transplant within 6 months or allogeneic hematopoietic stem cell transplant; 14. QTCF > 480ms, LVEF < 50%; 15. Urinary protein = 2 +, and urinary protein quantity >1.0 g in 24 hours within 7 days; 16. Has active hepatitis B or C; 17. Has psychotropic substances abuse or a mental disorder; 18. Has other conditions that make it inappropriate for the patient to be enrolled based on investigator's opinion. |
| Country | Name | City | State |
|---|---|---|---|
| China | Beijing Boren Hospital | Beijing | Beijing |
| China | Beijing Shijitan Hospital Affiliated to Capital Medical University | Beijing | Beijing |
| China | Cancer Hospital of Chinese Academy of Medical Sciences | Beijing | Beijing |
| China | The Fifth Medical Center of PLA General Hospital | Beijing | Beijing |
| China | The Third Hospital of Peking University | Beijing | Beijing |
| China | Affiliated Hospital of Binzhou Medical College | Binzhou | Shandong |
| China | The First Hospital of Jilin University | Changchun | Jilin |
| China | Hunan Cancer Hospital | Changsha | Hunan |
| China | Affiliated Zhongshan Hospital of Dalian University | Dalian | Liaoning |
| China | The First Affiliated Hospital of Dalian Medical University | Dalian | Liaoning |
| China | The Second Affiliated Hospital of Dalian Medical University | Dalian | Liaoning |
| China | Fujian Cancer Hospital | Fuzhou | Fujian |
| China | Union Hospital Affiliated to Fujian Medical University | Fuzhou | Fujian |
| China | Guangdong Provincial People's Hospital | Guangzhou | Guangdong |
| China | Sun Yat-sen University Cancer Center | Guangzhou | Guangdong |
| China | Anhui Cancer Hospital | Hefei | Anhui |
| China | The First Affiliated Hospital of Anhui Medical University | Hefei | Anhui |
| China | Huai'an first people's Hospital | Huaian | Jiangsu |
| China | The Second Hospital of Lanzhou University | Lanzhou | Gansu |
| China | Jiangxi Cancer Hospital | Nanchang | Jiangxi |
| China | Jiangsu Cancer Hospital | Nanjing | Jiangsu |
| China | Nanjing Drum Tower Hospital | Nanjing | Jiangsu |
| China | Guangxi Medical University Affiliated Tumor Hospital | Nanning | Guangxi Zhuang Autonomous Region |
| China | Nantong Tumor Hospital | Nantong | Jiangsu |
| China | Qingdao Central Hospital | Qingdao | Shandong |
| China | Shanghai Tongji Hospital | Shanghai | Shanghai |
| China | Fourth Hospital of Hebei Medical University | Shijiazhuang | Hebei |
| China | The First Affiliated Hospital of Suzhou University | Suzhou | Jiangsu |
| China | Hematology Hospital of Chinese Academy of Medical Sciences | Tianjin | Tianjin |
| China | Tianjin Cancer Hospital | Tianjin | Tianjin |
| China | Tianjin Medical University General Hospital | Tianjin | Tianjin |
| China | Tianjing People's Hospital | Tianjin | Tianjin |
| China | Weifang People's Hospital | Weifang | Shandong |
| China | Weihai Central Hospital | Weihai | Shandong |
| China | Weihai Municipal Hospital | Weihai | Shandong |
| China | Shanxi Provincial People's Hospital | Xi'an | Shanxi |
| China | The First Affiliated Hospital of Xiamen University | Xiamen | Fujian |
| China | Henan Cancer Hospital | Zhengzhou | Henan |
| China | The First Affiliated Hospital of Zhengzhou University | Zhengzhou | Henan |
| Lead Sponsor | Collaborator |
|---|---|
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Objective response rate (ORR) assessed by Independent Review Committee (IRC) | Percentage of subjects achieving complete response (CR) and partial response (PR) based on investigator. | up to 12 months | |
| Secondary | Disease control rate(DCR) | Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD). | up to 12 months | |
| Secondary | Duration of Response (DOR) | DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment. | up to 12 months | |
| Secondary | Progression-free survival (PFS) | PFS was defined as the time from the date of study enrollment to the date of the first of the following events, objective disease progression or death due to any cause. | up to 12 months | |
| Secondary | Overall survival (OS) | OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up. | up to 18 months | |
| Secondary | Biomarkers | To assess the changes of genes related to PI3K pathway and bypass in the tissues and / or plasma of enrolled patients. | up to 12 months |